Table 4 Overall survival estimates by patients and clinical characteristics in percentages
From: Predictors of survival in patients with sarcoma admitted to the intensive care unit
| Â | No of patients | No of deaths | 1-month overall survival estimate (95Â % CI) | 2-month overall survival estimate (95Â % CI) | 6-month overall survival estimate (95Â % CI) | p |
|---|---|---|---|---|---|---|
All patients | 172 | 135 | 64 (57–71) | 57 (49–64) | 41 (33–48) |  |
Age (years) | ||||||
 <65 | 139 | 109 | 64 (56–72) | 56 (47–64) | 41 (33–50) |  |
 ≥65 | 33 | 26 | 64 (45–77) | 61 (42–75) | 37 (21–54) | 0.91 |
Gender | ||||||
 Female | 93 | 72 | 66 (56–75) | 60 (49–69) | 45 (34–55) |  |
 Male | 79 | 63 | 62 (50–71) | 48 (37–59) | 36 (25–47) | 0.33 |
Histological diagnosis | ||||||
 Unclassified high-grade sarcoma | 43 | 34 | 67 (51–79) | 58 (42–71) | 46 (30–60) |  |
 Bonesa | 30 | 25 | 70 (50–83) | 60 (40–75) | 38 (21–55) |  |
 Vascularb | 17 | 16 | 64 (36–82) | 51 (25–72) | 32 (12–54) |  |
 GIST | 11 | 7 | 73 (37–90) | 64 (30–85) | 45 (17–71) |  |
 MFH | 11 | 8 | 55 (23–78) | 55 (23–78) | 36 (11–63) |  |
 Muscle | 10 | 9 | 60 (25–83) | 60 (25–83) | 20 (3–47) |  |
 Leiomyosarcoma | 13 | 7 | 84 (50–96) | 84 (50–96) | 75 (40–91) |  |
 Liposarcoma | 7 | 7 | 29 (4–61) | 29 (4–61) | 29 (4–61) |  |
 Synovial sarcoma | 9 | 6 | 56 (20–80) | 56 (20–80) | 56 (20–80) |  |
 Others | 21 | 16 | 56 (33–74) | 45 (23–65) | 28 (11–49) | 0.07 |
Status of malignancy | ||||||
 First course of chemotherapy | 29 | 22 | 66 (45–8) | 55 (35–71) | 41 (22–59) |  |
 Progression | 59 | 56 | 49 (36–61) | 37 (25–49) | 17 (9–27) |  |
 Stable disease or partial remission | 61 | 41 | 75 (62–84) | 72 (58–81) | 61 (47–72) |  |
 Complete remission | 4 | 2 | 100 | 100 | 75 (13–96) |  |
 Mixed response | 6 | 5 | 67 (19–90) | 67 (19–90) | 67 (19–90) |  |
 Unknown | 13 | 9 | 68 (36–87) | 68 (36–87) | 29 (7–56) | <0.0001 |
Site of malignancy | ||||||
 Head and neck | 15 | 11 | 52 (25–73) | 52 (25–73) | 29 (9–53) |  |
 Thoracic | 43 | 33 | 67 (51–79) | 60 (43–73) | 46 (30–60) |  |
 Abdomen | 71 | 57 | 62 (49–72) | 53 (41–64) | 37 (26–48) |  |
 Extremities | 43 | 34 | 7 (54–81) | 63 (47–75) | 46 (31–60) | 0.86 |
Organ metastasis | ||||||
 Lung | ||||||
  No | 86 | 62 | 66 (55–75) | 59 (48–69) | 46 (35–56) |  |
  Yes | 86 | 73 | 62 (51–72) | 55 (43–65) | 36 (25–46) | 0.02 |
 Liver | ||||||
  No | 142 | 109 | 66 (58–73) | 59 (51–67) | 46 (37–54) |  |
  Yes | 30 | 26 | 56 (36–72) | 45 (27–62) | 17 (6–33) | 0.0093 |
 Other | ||||||
  No | 79 | 55 | 66 (54–75) | 63 (51–73) | 49 (38–60) |  |
  Yes | 93 | 80 | 63 (52–72) | 52 (41–62) | 33 (24–43) | 0.0091 |
 Number of organ metastases | ||||||
  0 | 42 | 25 | 71 (55–83) | 69 (53–81) | 59 (43–72) |  |
  1 | 54 | 43 | 59 (45–71) | 53 (39–65) | 40 (26–53) |  |
  2+ | 76 | 67 | 64 (52–74) | 53 (41–64) | 31 (21–42) | 0.001 |
 Localized disease | ||||||
  No | 130 | 110 | 62 (53–7) | 53 (44–61) | 34 (26–43) |  |
  Yes | 42 | 25 | 71 (55–83) | 69 (53–81) | 59 (43–72) | <0.0001 |
Treatment | ||||||
 Current chemotherapy regimen | ||||||
  None | 43 | 31 | 57 (41–7) | 52 (36–66) | 39 (24–53) |  |
  Adriamycin-based chemotherapy | 68 | 51 | 69 (56–78) | 66 (53–76) | 51 (38–63) |  |
  Gemcitabine-based therapy | 20 | 18 | 5 (27–69) | 45 (23–65) | 25 (9–45) |  |
  Targeted therapy | 41 | 35 | 71 (54–82) | 54 (37–67) | 34 (20–49) | 0.31 |
 Radiation | ||||||
  No | 109 | 85 | 63 (54–72) | 59 (49–67) | 39 (29–48) |  |
  Yes | 62 | 50 | 65 (52–76) | 53 (40–65) | 43 (30–55) | 0.86 |
Clinical conditions present at ICU admission | ||||||
 Anemia | 144 | 113 | 66 (57–73) | 59 (50–66) | 43 (35–51) | 0.60 |
 Hypotension | 92 | 73 | 57 (46–66) | 51 (40–61) | 42 (32–52) | 0.96 |
 Septic shock | 53 | 44 | 49 (35–62) | 45 (32–58) | 33 (21–46) | 0.10 |
 Bacteremia | 21 | 17 | 57 (34–75) | 57 (34–75) | 43 (22–62) | 0.58 |
 Thrombocytopenia | 86 | 63 | 71 (60–79) | 64 (52–73) | 49 (37–59) | 0.037 |
 Respiratory failure | 74 | 62 | 46 (34–56) | 41 (30–52) | 26 (16–37) | <0.0001 |
 Acidosis | 70 | 58 | 47 (35–58) | 41 (30–53) | 35 (24–46) | 0.011 |
 Altered mental status | 65 | 57 | 52 (39–63) | 42 (30–54) | 25 (15–36) | 0.001 |
 Abnormal glucose | 60 | 50 | 60 (46–71) | 49 (36–61) | 25 (14–37) | 0.017 |
 Acute renal failure | 58 | 49 | 48 (35–60) | 40 (27–52) | 29 (18–41) | 0.016 |
 Pancytopenia | 58 | 41 | 79 (66–88) | 74 (61–83) | 57 (43–69) | 0.006 |
 Respiratory abnormality | 53 | 38 | 73 (59–83) | 64 (49–75) | 49 (35–62) | 0.036 |
 Pneumonia | 51 | 42 | 53 (38–65) | 49 (35–62) | 35 (22–48) | 0.41 |
 Neutropenia (ANC <1500/mm3) | 51 | 36 | 78 (64–87) | 70 (56–81) | 58 (43–70) | 0.013 |
 Cardiac dysrhythmia | 35 | 26 | 57 (39–72) | 51 (34–66) | 46 (29–61) | 0.96 |
 Heart failure | 32 | 25 | 63 (44–77) | 56 (37–71) | 53 (34–68) | 0.80 |
 Hypertension | 25 | 15 | 80 (58–91) | 71 (48–85) | 61 (39–78) | 0.049 |
 Malnutrition (protein/calorie) NOS | 23 | 21 | 60 (37–77) | 60 (37–77) | 28 (11–47) | 0.047 |
 Hemorrhage (non–gastrointestinal) | 15 | 9 | 64 (34–83) | 64 (34–83) | 47 (19–71) | 0.44 |
 Other pulmonary insufficiency | 14 | 11 | 71 (41–88) | 64 (34–83) | 64 (34–83) | 0.71 |
 Gastrointestinal hemorrhage | 13 | 9 | 62 (31–82) | 54 (25–76) | 38 (14–63) | 0.51 |
 Cardiac arrest | 11 | 8 | 27 (7–54) | 27 (7–54) | 27 (7–54) | 0.17 |
 Pulmonary embolism | 11 | 10 | 73 (37–90) | 63 (29–84) | 32 (8–59) | 0.21 |
 Atrial fibrillation | 10 | 7 | 70 (33–89) | 70 (33–89) | 6 (25–83) | 0.40 |
 Seizures | 9 | 8 | 67 (28–88) | 44 (14–72) | 30 (5–61) | 0.54 |
ICU admission data | ||||||
 Charlson comorbidity index | ||||||
 ≤2 | 26 | 15 | 69 (48–83) | 69 (48–83) | 54 (33–71) |  |
 >2 | 146 | 120 | 63 (55–71) | 55 (46–62) | 38 (30–46) | 0.0031 |
 Charlson comorbidity index | ||||||
  <6 | 42 | 25 | 71 (55–83) | 69 (53–81) | 59 (43–72) |  |
  ≥6 | 130 | 110 | 62 (53–70) | 53 (44–61) | 34 (26–43) | <0.0001 |
 SOFA maximum score | ||||||
  <8 | 79 | 60 | 82 (72–89) | 71 (60–80) | 49 (38–60) |  |
  ≥8 | 93 | 75 | 49 (39–59) | 45 (34–55) | 33 (24–43) | 0.005 |
 SOFA discharge score | ||||||
  <5 | 77 | 59 | 80 (69–88) | 71 (59–80) | 47 (35–58) |  |
  ≥5 | 95 | 76 | 51 (41–61) | 46 (36–56) | 36 (26–45) | 0.12 |
 No. organ failures | ||||||
  1 | 59 | 47 | 76 (63–85) | 69 (56–79) | 53 (40–65) |  |
  ≥2 | 113 | 88 | 58 (48–66) | 50 (41–59) | 34 (25–43) | 0.12 |